Rare Cell Isolation Market Size & Trends

In the year 2023, the global economic footprint of the rare cell isolation domain was marked at approximately USD 1.83 billion. Looking ahead, this sector is anticipated to flourish, charting a growth trajectory with a Compound Annual Growth Rate (CAGR) of 9.71% spanning from 2024 to 2030. This significant expansion is fueled by the relentless progress in biotechnology and the escalating imperative for precision medicine. The spotlight is on rare cells – including circulating tumor cells (CTCs), stem cells, and fetal cells – which are instrumental in the early identification of diseases, the careful observation of treatment efficacy, and the development of therapies tailored to individual needs.

The rare cell isolation market itself is a vibrant ecosystem, encompassing a diverse suite of technologies and methodologies meticulously engineered to isolate and analyze these scarce cellular entities from biological matrices such as blood, tissue, and other bodily fluids. The primary innovators in this space are continuously pushing the boundaries, developing increasingly efficient and precise isolation techniques to meet the burgeoning demands across clinical diagnostics, scientific research, and therapeutic interventions.

Get a preview of the latest developments in the Rare Cell Isolation Market; Download your FREE sample PDF copy today and explore key data and trends

Several firms, including NanoString Technologies, Levitas Bio, & Bionano Genomics, have implemented product development strategies and increased their offerings. For example, in April 2022, Levitas Bio announced the launch of the LeviCell EOS System, a next-generation cell isolation platform. The new product allows for targeted selection of viable cells & has a better throughput than the company's previous products. Furthermore, the COVID-19 pandemic has allowed researchers to examine and comprehend this novel infectious virus and develop medicines and diagnostic tools for it. A primary driver of the market growth is the increasing prevalence of cancer and other chronic diseases.

As per the American Cancer Society, in 2023, in the U.S. alone, more than 1.9 million new cases of cancer are projected to be diagnosed. The ability to isolate and analyze rare cells like CTCs provides critical insights into tumor biology and the metastatic process, aiding in early detection and developing targeted treatment strategies. Personalized medicine, which customizes healthcare based on individual genetic profiles, has fueled the demand for advanced rare cell isolation technologies. In response, companies are developing novel platforms that integrate isolation and analysis, improving the efficiency and accuracy of detecting these rare cells. For instance, advancements in next-generation sequencing (NGS) and digital PCR are enhancing the analytical capabilities of isolated rare cells, paving the way for more comprehensive and personalized diagnostic solutions.

Recent developments in the market underscore the competitive landscape and the pace of innovation in rare cell isolation. For example, in 2024, RareCyte Inc. announced the launch of its novel platform, CyteFinder II, which enhances the detection and analysis of rare cells through advanced imaging and AI-driven algorithms. This platform is expected to improve clinical diagnostics and research workflow significantly. Similarly, Menarini Silicon Biosystems recently expanded its product portfolio with the DEPArray PLUS system, designed to provide highly precise rare cell isolation for liquid biopsies and personalized medicine applications.

Detailed Segmentation

Products Insights

The reagent & kits segment dominated the market in 2023 and is anticipated to grow at a higher CAGR of 10.25% during the forecast period. The development of advanced reagents and kits has significantly improved the efficiency and precision of isolating rare cells, such as CTCs and stem cells. These specialized reagents and kits are designed to enhance the sensitivity and specificity of isolation methods, making them indispensable for both research and clinical applications.

Cell Type Insights

The stem cell segment dominated the market and accounted for a share of 39.46% in 2023. In addition, this segment is anticipated to grow at the highest CAGR of 11.23% from 2024 to 2030. The segment growth is attributed to the unique regenerative capabilities and therapeutic potential of stem cells, which make them a focal point in medical research and clinical applications. The broad range of applications drives a high demand for efficient and reliable stem cell isolation techniques.

Technology Insights

The microfluidics-based techniques segment held the largest market share in 2023. Microfluidics-based techniques dominate the market due to their unique advantages and innovative capabilities catering to the growing needs of research and clinical applications. These techniques leverage the precise control and manipulation of fluids at the microscale, enabling the isolation of rare cells, such as CTCs and stem cells, with unprecedented efficiency and accuracy. One of the primary reasons for the dominance of microfluidics-based techniques is their ability to handle and process very small sample volumes with high throughput. This is particularly advantageous in clinical diagnostics, where the availability of patient samples, such as blood, can be limited. Microfluidic platforms can efficiently process these small volumes to isolate rare cells without significant loss, making them ideal for clinical applications.

Regional Insights

The North America rare cell isolation market dominated the global industry and accounted for a share of 40.26% in 2023, attributed to the region’s advanced healthcare infrastructure, strong presence of leading biotechnology firms, and significant funding for cell research. Furthermore, growing healthcare expenditure, increasing awareness of cell therapies, and supportive government initiatives boost the market growth.

Key Rare Cell Isolation Company Insights

Key players operating in the market undertake various initiatives to strengthen their market presence and increase the reach of their products. Strategies, such as expansion activities and partnerships, play a key role in propelling the market growth.

Key Rare Cell Isolation Companies:

The following are the leading companies in the Rare Cell Isolation market. These companies collectively hold the largest market share and dictate industry trends.

• Miltenyi Biotec
• Thermo Fisher Scientific, Inc.
• Danaher
• QIAGEN N.V.
• Bio-techne
• STEMCELL Technologies
• CELLENION
• RareCyte
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.

Rare Cell Isolation Market Segmentation

Grand View Research has segmented global rare cell isolation market on the basis of technology, cell type, product, and region:

Rare Cell Isolation Product Outlook (Revenue, USD Billion, 2018 - 2030)

• Reagent & Kits
• Instrument

Rare Cell Isolation Cell Type Outlook (Revenue, USD Billion, 2018 - 2030)

• Circulating Tumor Cells
• Stem Cells
• Fetal Cells
• Rare Immune Cells
• Circulating Endothelial Cells
• Other Rare Cell Types

Rare Cell Isolation Technology Outlook (Revenue, USD Billion, 2018 - 2030)

• Magnetic-bead Separation
• Fluorescence-activated Cell Sorting
• Microfluidics-based Techniques

Rare Cell Isolation Regional Outlook (Revenue, USD Billion, 2018 - 2030)

• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• China
• Japan
• India
• South Korea
• Australia
• Thailand
• Latin America
• Brazil
• Argentina
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Curious about the Rare Cell Isolation Market? Download your FREE sample copy now and get a sneak peek into the latest insights and trends.

Recent Developments

• In June 2024, Bio-Rad Introduced Celselect Slides 2.0 to Enhance Rare Cell & Circulating Tumor Cell Enrichment for Cancer Research
• In March 2024, Bio-Rad introduced validated antibodies for rare cell & circulating tumor cell enumeration
• In February 2024, Akadeum Life Sciences, Inc. and NanoCellect Biomedical, Inc. announced an additional partnership to improve rare-cell workflows. Both companies research and manufacture innovative and simple cell-sorting technology